Clinical trials: Compensated Chronic Hepatitis B
Chronic Hepatitis B
Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)
The purpose of this study is to compare the safety, tolerability and effectiveness of 12 weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg once daily (QD) taken together versus tenofovir DF 300 mg once…
- Trial name
- NCT00804622
- Testing
- telbivudine, tenofovir disproxil fumarate, telbivudine plus tenofovir disproxil fumarate
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The University of Hong Kong
Chronic Hepatitis B
Study of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
To analyze the incidence of liver cancer after entecavir administration among patients with low viral load and cirrhosis due to chronic hepatitis B infection.
- Trial name
- NCT04646928
- Where
- 11 sites in South Korea
- Volunteers
- 245 people
- Sponsor
- CHA University
HBeAg(-) Chronic Hepatitis B With Compensated Liver Function
A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function
A double-blind randomized, parallel, multicenter with 48 weeks of treatment period. The purpose of this study is to compare the safety and antiviral activity of 48-week Clevudine and Adefovir dipivoxil in HBeAg(-) Chronic…
- Trial name
- NCT00641082
- Testing
- Clevudine, Adefovir dipivoxil
- Where
- 2 sites in South Korea
- Volunteers
- 43 people
- Sponsor
- Bukwang Pharmaceutical
Chronic Hepatitis B
Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B
This study is being conducted to compare the effectiveness and safety of telbivudine (LdT) and lamivudine in Chinese adults.
- Trial name
- NCT00131742
- Testing
- telbivudine, lamivudine
- Where
- China
- Sponsor
- Novartis
Chronic Hepatitis B
Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B
This research study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (telbivudine) versus adefovir dipivoxil, a drug approved by the Food and Drug Administration (FDA) for the…
- Trial name
- NCT00115245
- Testing
- Telbivudine (LdT), Adefovir Dipivoxil
- Where
- 15 sites in United States, Australia and 7 more
- Sponsor
- Novartis
Compensated Chronic Hepatitis B
Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks
The purpose of this study is to investigate the efficacy of telbivudine in Blacks/African Americans and Hispanics/Latinos with compensated chronic hepatitis B during 52 weeks of treatment
- Trial name
- NCT00862706
- Testing
- Telbivudine/LDT600A
- Where
- 6 sites in United States, Puerto Rico
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Chronic
Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Chronic Hepatitis B infection (CHB) is known as the most frequently identified cause of liver disease that predisposes patients to the development of hepatocellular carcinoma (HCC).
- Trial name
- NCT02224456
- Testing
- Tenofovir disoproxil fumarate
- Where
- 19 sites in China
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Compensated Chronic Hepatitis B
Efficacy Optimizing Research of Lamivudine Therapy
The purpose of this study is to compare the adefovir early add-on to rescue therapy strategy, and also explore the efficacy of Lamivudine and adefovir de-novo combination therapy.
- Trial name
- EXPLORE (NCT01088009)
- Testing
- lamivudine, lamivudine, adefovir
- Where
- 24 sites in China
- Volunteers
- 366 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B, Chronic
To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)
This study is to evaluate the antiviral efficacy of add-on adefovir to telbivudine in non-responders to telbivudine monotherapy after 24 and 36 initial weeks.
- Trial name
- NCT00537537
- Testing
- Telbivudine
- Where
- 3 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis B
Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B
This study is designed to evaluate the efficacy and safety of telbivudine 600mg versus adefovir dipivoxil 10mg in patients with compensated chronic hepatitis B.
- Trial name
- NCT00606099
- Testing
- telbivudine, adefovir dipivoxil
- Where
- 3 sites in United States
- Sponsor
- Novartis
Hepatitis B, Chronic
EFFORT Extension Study
The purpose of this study is to to prove that the long-term efficacy of strategy of treatment adjustment at W24 according to virological response based on ROADMAP concept is better than standard of care strategy.
- Trial name
- EFFORT-Ex (NCT01529255)
- Testing
- telbivudine (ROADMAP), Telbivudine (Standard of Care)
- Where
- 24 sites in China
- Volunteers
- 576 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B, Chronic
Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B
This study will explore efficacy and safety of Telbivudine in the fifth year of treatment.
- Trial name
- NCT00646503
- Testing
- Telbivudine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Novartis
Chronic Hepatitis B
An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B
This study is to evaluate the safety of telbivudine for up to 21 months of open-label treatment in patients with chronic hepatitis B who have completed the CLDT600A2407 trial.
- Trial name
- NCT00467545
- Testing
- telbivudine
- Where
- 6 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Chronic, Hepatocellular Carcinoma
Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
The current first-line treatment for HBV is long-term oral antiviral drugs to inhibit HBV DNA replication. First-line antiviral drugs recommended by the Chinese 2015 Hepatitis B Guidelines include ETV and TDF.
- Conditions
- Hepatitis B, Chronic, Hepatocellular Carcinoma, Compensated Cirrhosis
- Trial name
- NCT04160897
- Testing
- Entecavir, Tenofovir Disoproxil
- Where
- China
- Volunteers
- 4,000 people
- Sponsor
- Qing XIe
Chronic Hepatitis C, Chronic Hepatitis B
The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China
Subjects can be classified into two groups, Group 1 include non-cirrhotic patients, Group 2 include cirrhotic patients. All the patients will be received prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12…
- Trial name
- BDTAF (NCT04997564)
- Testing
- Tenofovir Alafenamide 25 MG, Sofosbuvir / Velpatasvir
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University First Hospital
Hepatitis B Virus
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
The purpose of this study is to compare the safety, tolerability and effectiveness of 12 weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg one daily (OD) taken together vs.
- Trial name
- NCT00805675
- Testing
- Telbivudine, Tenofovir, Telbivudine plus tenofovir
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis B
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
This study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) with Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the…
- Trial name
- NCT00057265
- Testing
- telbivudine or lamivudine
- Where
- 11 sites in United States, South Korea and 4 more
- Sponsor
- Novartis
Chronic Hepatitis B
Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients
This study is designed to compare the efficacy and safety of adefovir dipivoxil 10 mg with lamivudine 100 mg in Japanese patients with compensated chronic hepatitis B over 52-week periods.
- Trial name
- NCT00316719
- Testing
- LAM group, ADV group
- Volunteers
- 105 people
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic Hepatitis B
Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B
This exploratory study is designed to determine the early viral kinetic profile during treatment with telbivudine or entecavir at multiple time points over 12 weeks.
- Trial name
- NCT00412529
- Testing
- Entecavir, Telbivudine
- Where
- 8 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Compensated Chronic Hepatitis B
Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B
The purpose of this trial is to provide data of absence of inflammation in patient liver histology after long-term telbivudine treatment and thus help investigators to make a comprehensive judgment on treatment discontinuation in…
- Trial name
- NCT00877149
- Testing
- telbivudine/LDT600
- Where
- 4 sites in China
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals